Kammer R B, Short L J
Postgrad Med J. 1979;55 Suppl 4:93-9.
Cefaclor, a new semisynthetic cephalosporin antibiotic for oral use, was studied by 62 clinical investigators in 6 countries in 1493 adult and paediatric patients. The pooled data reveal that satisfactory clinical responses were obtained in 80% of urinary tract infections, 87% of upper respiratory infections, 90% of cases of otitis media, 99% of lower respiratory tract infections, and 96% of skin and skin structure infections. Administration of this antibiotic was associated with a low incidence of adverse reactions including gastrointestinal (2.6%) and hypersensitivity reactions (1.5%). Of particular clinical interest were the outstanding results obtained in the treatment of otitis media and lower respiratory tract infections.
头孢克洛是一种新型口服半合成头孢菌素抗生素，6个国家的62名临床研究人员对1493例成人和儿童患者进行了研究。汇总数据显示，尿路感染的临床有效率为80%，上呼吸道感染为87%，中耳炎为90%，下呼吸道感染为99%，皮肤及皮肤结构感染为96%。使用这种抗生素的不良反应发生率较低，包括胃肠道反应（2.6%）和过敏反应（1.5%）。尤其值得临床关注的是，在中耳炎和下呼吸道感染的治疗中取得了出色的效果。
